Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anti-tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone acetate; Enzalutamide; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PRIMCAB
- Sponsors Sanofi
- 07 Dec 2017 Planned End Date changed from 15 Nov 2017 to 15 Feb 2018.
- 07 Dec 2017 Planned primary completion date changed from 15 Nov 2017 to 15 Feb 2018.
- 13 Nov 2017 Planned End Date changed from 1 Dec 2018 to 15 Nov 2017.